{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:18:03Z","timestamp":1720527483090},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.meegid.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T17:01:42Z","timestamp":1489683702000},"page":"167-172","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study"],"prefix":"10.1016","volume":"51","author":[{"given":"Lucio","family":"Boglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Simona","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2017.03.014_bb0005","author":"AIFA, I.A.o.D"},{"key":"10.1016\/j.meegid.2017.03.014_bb0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s15010-007-7132-6","article-title":"Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin","volume":"36","author":"Antonini","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.meegid.2017.03.014_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013771","article-title":"IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV\/HIV-1 coinfected patients","volume":"5","author":"Aparicio","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2017.03.014_bb0020","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.24201","article-title":"Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C\/T polymorphism in predicting antiviral response in chronic hepatitis C","volume":"53","author":"Bitetto","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2017.03.014_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2015.01.014","article-title":"Treatment optimization of naive HCV-1 patients using IL28B, RVR and fibrosis stage","volume":"116","author":"Boglione","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2017.03.014_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.antiviral.2014.03.016","article-title":"Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms","volume":"106","author":"Boglione","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2017.03.014_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1517\/14656566.2014.889116","article-title":"New antiviral agents for the treatment of hepatitis C: ABT-450","volume":"15","author":"Carrion","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.meegid.2017.03.014_bb0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.meegid.2017.03.014_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"Chhatwal","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.meegid.2017.03.014_bb0050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/FTD.0b013e318272e55a","article-title":"Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG\/IFN-RBV treatment","volume":"34","author":"D'Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.meegid.2017.03.014_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients","volume":"835","author":"D'Avolio","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.meegid.2017.03.014_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"EASL","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2017.03.014_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MEG.0000000000000506","article-title":"Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors","volume":"28","author":"Feillant","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2017.03.014_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2014.02.005","article-title":"The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?","volume":"105","author":"Feld","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.meegid.2017.03.014_bb0075","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2017.03.014_bb0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/apt.12823","article-title":"Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naive patients with genotype 1 HCV infection in Italy","volume":"40","author":"Messori","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2017.03.014_bb0085","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3748\/wjg.v18.i12.1339","article-title":"Chronic hepatitis C: treat or wait? Medical decision making in clinical practice","volume":"18","author":"Niederau","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2017.03.014_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"Rein","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.meegid.2017.03.014_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/liv.12066","article-title":"Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?","volume":"33","author":"Shiffman","year":"2013","journal-title":"Liver Int."},{"key":"10.1016\/j.meegid.2017.03.014_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40258-013-0064-7","article-title":"A critical systematic review of budget impact analyses on drugs in the EU countries","volume":"12","author":"van de Vooren","year":"2014","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"Suppl.1","key":"10.1016\/j.meegid.2017.03.014_bb0105","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effect of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.meegid.2017.03.014_bb0110","series-title":"WHO Handbook fo Reporting Results of Cancer Treatment","first-page":"132","article-title":"Section VIII: WHO toxicity Grading Scale for determining the severity of adverse events","author":"WHO","year":"2003"},{"key":"10.1016\/j.meegid.2017.03.014_bb0115","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2015-310421","article-title":"Hepatitis C virus treatment in the real world: optimising treatment and access to therapies","volume":"64","author":"Zoulim","year":"2015","journal-title":"Gut"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134817300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134817300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T17:14:04Z","timestamp":1568913244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134817300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":23,"alternative-id":["S1567134817300850"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2017.03.014","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}